Приказ основних података о документу
Clinically important drug interactions with opioid and non-opioid analgesics
Klinički značajne interakcije opioidnih i neopioidnih analgetika
dc.creator | Vezmar-Kovačević, Sandra | |
dc.creator | Vučićević, Katarina | |
dc.creator | Topić-Vučenović, Valentina | |
dc.creator | Rajkovača, Zvezdana | |
dc.creator | Miljković, Branislava | |
dc.date.accessioned | 2019-09-02T12:09:10Z | |
dc.date.available | 2019-09-02T12:09:10Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0004-1963 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/3269 | |
dc.description.abstract | Patients often seek advise from doctors and pharmacists about pain treatment. Opioid and non-opioid analgesics are the most commonly used drugs in the treatment of pain, but they have potential for pharmacodynamic and pharmacokinetic drug-drug interactions. The risk of central nervous system depression and respiratory depression is increased if opioid analgesics are used with anxiolytics, first-generation antihistamines, and antidepressants. Serotonin syndrome can occur if tramadol and fentanyl are used with selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline inhibitors, monoamino oxidase inhibitors, etc. Decreased elimination of opioid analgesics as a consequence of CYP2D6 and CYP3A4 isoenzyme inhibition can result in their increased efficacy but sedation and respiratory depression have also been reported. Caution is needed when non-steroidal anti-inflammatory drugs (NSAIDs) are used concomitantly with other drugs that cause bleeding such as anticoagulants and SSRIs or drugs that decrease the elimination of NSAIDs by inhibition of CYP2C9. NSAIDs can antagonize the effect of antihypertensives, and interaction with angiotensin-converting enzyme inhibitors may result in renal failure. In comparison with opioid analgesics and NSAIDs, paracetamol has the lowest potential for clinically significant interactions. The prophylactic administration of paracetamol after vaccination should be avoided and patients should be advised not to use alcohol during therapy. | en |
dc.description.abstract | Pacijenti se često obraćaju lekarima i farmaceutima za pomoć u terapiji bola. Opioidni i neopioidni analgetici su najčešće lekovi izbora u terapiji bola ali imaju veliki potencijal za stupanje u farmakodinamske i farmakokinetičke interakcije sa drugim lekovima. Kod opioidnih analgetika povećan je rizik od pojave depresije centralnog nervnog sistema i respiratorne depresije ukoliko se ovi lekovi primenjuju sa anksioliticima, antihistaminicima prve generacije i antidepresivima. Serotoninski sindrom se može javiti ukoliko se tramadol i fentanil primenjuju sa selektivnim inhibitorima preuzimanja serotonina (SSRI), inhibitorima preuzimanja serotonina i noradrenalina, inhibitorima monoamino-oksidaze i dr. Usporena eliminacija opioidnih analgetika, kao posledica inhibicije izoenzima CYP2D6 i CYP3A4 može rezultirati njihovom povećanom efikasnošću ali i pojavom sedacije i respiratorne depresije. Oprez je potreban kada se nesteroidni antiinflamatorni lekovi (NSAIL) primenjuju istovremeno sa drugim lekovima koji mogu dovesti do krvarenja poput antikoagulanasa i SSRI ili lekovima koji usporavaju eliminaciju NSAIL inhibicijom izoenzima CYP2C9. NSAIL mogu antagonizovati dejstvo antihipertenziva, a interakcija sa inhibitorima angiotenzin-konvertujućeg enzima može rezultirati bubrežnom insuficijencijom. U poređenju sa opioidnim analgeticima i NSAIL, paracetamol ima najmanji potencijal za stupanje u klinički značajne interakcije. Potrebno je izbegavati profilaktičku primenu paracetamola nakon vakcinacije i skrenuti pacijentima pažnju da ne primenjuju alkohol u toku terapije. | sr |
dc.publisher | Savez farmaceutskih udruženja Srbije, Beograd | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-sa/4.0/ | |
dc.source | Arhiv za farmaciju | |
dc.subject | clinically important drug interactions | en |
dc.subject | opioid and non-opioid analgesics | en |
dc.subject | mechanism of interaction | en |
dc.subject | pharmacists | en |
dc.subject | klinički značajne interakcije | sr |
dc.subject | opioidni i neopioidni analgetici | sr |
dc.subject | mehanizam interakcija | sr |
dc.subject | farmaceut | sr |
dc.title | Clinically important drug interactions with opioid and non-opioid analgesics | en |
dc.title | Klinički značajne interakcije opioidnih i neopioidnih analgetika | sr |
dc.type | article | |
dc.rights.license | BY-SA | |
dcterms.abstract | Миљковић, Бранислава; Везмар-Ковачевић, Сандра; Вучићевић, Катарина; Топић-Вученовић, Валентина; Рајковача, Звездана; Клинички значајне интеракције опиоидних и неопиоидних аналгетика; Клинички значајне интеракције опиоидних и неопиоидних аналгетика; | |
dc.citation.volume | 69 | |
dc.citation.issue | 1 | |
dc.citation.spage | 1071 | |
dc.citation.epage | 1083 | |
dc.citation.other | 69(1): 1071-1083 | |
dc.citation.rank | M52 | |
dc.identifier.doi | 10.5937/ArhFarm1901071V | |
dc.identifier.scopus | 2-s2.0-85064691872 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/1843/3267.pdf | |
dc.type.version | publishedVersion |